Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

  1. Casadei-Gardini, Andrea
  2. Rimini, Margherita
  3. Kudo, Masatoshi
  4. Shimose, Shigeo
  5. Tada, Toshifumi
  6. Suda, Goki
  7. Goh, Myung Ji
  8. Jefremow, André ORCID logo
  9. Scartozzi, Mario
  10. Cabibbo, Giuseppe ORCID logo
  11. Campani, Claudia
  12. Tamburini, Emiliano
  13. TOVOLI, FRANCESCO ORCID logo
  14. Ueshima, Kazuomi
  15. Aoki, Tomoko
  16. Iwamoto, Hideki
  17. Torimura, Takuji
  18. Kumada, Takashi
  19. Hiraoka, Atsushi
  20. Atsukawa, Masanori
  21. Itobayashi, Ei
  22. Toyoda, Hidenori
  23. SAKAMOTO, NAOYA ORCID logo
  24. Sho, Takuya
  25. Kang, Wonseok ORCID logo
  26. Siebler, Jürgen
  27. Neurath, Markus Friedrich
  28. Burgio, Valentina ORCID logo
  29. Cascinu, Stefano

Download
LIC525145.pdf 385,33KB
WeightNameValue
1000 Titel
  • Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
1000 Autor/in
  1. Casadei-Gardini, Andrea |
  2. Rimini, Margherita |
  3. Kudo, Masatoshi |
  4. Shimose, Shigeo |
  5. Tada, Toshifumi |
  6. Suda, Goki |
  7. Goh, Myung Ji |
  8. Jefremow, André |
  9. Scartozzi, Mario |
  10. Cabibbo, Giuseppe |
  11. Campani, Claudia |
  12. Tamburini, Emiliano |
  13. TOVOLI, FRANCESCO |
  14. Ueshima, Kazuomi |
  15. Aoki, Tomoko |
  16. Iwamoto, Hideki |
  17. Torimura, Takuji |
  18. Kumada, Takashi |
  19. Hiraoka, Atsushi |
  20. Atsukawa, Masanori |
  21. Itobayashi, Ei |
  22. Toyoda, Hidenori |
  23. SAKAMOTO, NAOYA |
  24. Sho, Takuya |
  25. Kang, Wonseok |
  26. Siebler, Jürgen |
  27. Neurath, Markus Friedrich |
  28. Burgio, Valentina |
  29. Cascinu, Stefano |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-07-11
1000 Erschienen in
1000 Quellenangabe
  • 11(6):527-539
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1159/000525145 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801178/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We included 1,325 patients with HCC and treated with lenvatinib in our analysis. Median OS was 16.1 months. Overall response rate was 38.5%. Multivariate analysis for OS highlighted that HBsAg positive, NLR &amp;#x3e;3, and AST &amp;#x3e;38 were independently associated with poor prognosis in all models. Conversely, NAFLD/NASH-related etiology was independently associated with good prognosis. Median progression-free survival was 6.3 months. Multivariate analysis for progression-free survival revealed that NAFLD/NASH, BCLC, NLR, and AST were independent prognostic factors for progression-free survival. A proportion of 75.2% of patients suffered from at least one adverse effect during the study period. Multivariate analysis exhibited the appearance of decreased appetite grade ≥2 versus grade 0–1 as an independent prognostic factor for worse progression-free survival. 924 patients of 1,325 progressed during lenvatinib (69.7%), and 827 of them had a follow-up over 2 months from the beginning of second-line treatment. From first-line therapy, the longest median OS was obtained with the sequence lenvatinib and immunotherapy (47.0 months), followed by TACE (24.7 months), ramucirumab (21.2 months), sorafenib (15.7 months), regorafenib (12.7 months), and best supportive care (10.8 months). &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib. </jats:p>
1000 Sacherschließung
lokal Outcome
lokal Lenvatinib
lokal Second line
lokal Nonalcoholic fatty liver disease
lokal Neutrophils to lymphocyte ratio
lokal Nonalcoholic steatohepatitis
lokal ALBI
lokal Hepatocellular carcinoma
lokal Tyrosine kinase inhibitors
lokal Research Article
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q2FzYWRlaS1HYXJkaW5pLCBBbmRyZWE=|https://frl.publisso.de/adhoc/uri/UmltaW5pLCBNYXJnaGVyaXRh|https://frl.publisso.de/adhoc/uri/S3VkbywgTWFzYXRvc2hp|https://frl.publisso.de/adhoc/uri/U2hpbW9zZSwgU2hpZ2Vv|https://frl.publisso.de/adhoc/uri/VGFkYSwgVG9zaGlmdW1p|https://frl.publisso.de/adhoc/uri/U3VkYSwgR29raQ==|https://frl.publisso.de/adhoc/uri/R29oLCBNeXVuZyBKaQ==|https://orcid.org/0000-0002-2041-269X|https://frl.publisso.de/adhoc/uri/U2NhcnRvenppLCBNYXJpbw==|https://orcid.org/0000-0002-0946-3859|https://frl.publisso.de/adhoc/uri/Q2FtcGFuaSwgQ2xhdWRpYQ==|https://frl.publisso.de/adhoc/uri/VGFtYnVyaW5pLCBFbWlsaWFubw==|https://orcid.org/0000-0002-8350-1155|https://frl.publisso.de/adhoc/uri/VWVzaGltYSwgS2F6dW9taQ==|https://frl.publisso.de/adhoc/uri/QW9raSwgVG9tb2tv|https://frl.publisso.de/adhoc/uri/SXdhbW90bywgSGlkZWtp|https://frl.publisso.de/adhoc/uri/VG9yaW11cmEsIFRha3VqaQ==|https://frl.publisso.de/adhoc/uri/S3VtYWRhLCBUYWthc2hp|https://frl.publisso.de/adhoc/uri/SGlyYW9rYSwgQXRzdXNoaQ==|https://frl.publisso.de/adhoc/uri/QXRzdWthd2EsIE1hc2Fub3Jp|https://frl.publisso.de/adhoc/uri/SXRvYmF5YXNoaSwgRWk=|https://frl.publisso.de/adhoc/uri/VG95b2RhLCBIaWRlbm9yaQ==|https://orcid.org/0000-0003-0061-059X|https://frl.publisso.de/adhoc/uri/U2hvLCBUYWt1eWE=|https://orcid.org/0000-0001-9578-8424|https://frl.publisso.de/adhoc/uri/U2llYmxlciwgSsO8cmdlbg==|https://frl.publisso.de/adhoc/uri/TmV1cmF0aCwgTWFya3VzIEZyaWVkcmljaA==|https://orcid.org/0000-0002-0146-4136|https://frl.publisso.de/adhoc/uri/Q2FzY2ludSwgU3RlZmFubw==
1000 Hinweis
  • DeepGreen-ID: dda19275a309427ab280f0a0db372011 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6473669.rdf
1000 Erstellt am 2024-03-21T13:51:30.287+0100
1000 Erstellt von 322
1000 beschreibt frl:6473669
1000 Zuletzt bearbeitet 2024-05-07T14:00:38.943+0200
1000 Objekt bearb. Tue May 07 14:00:38 CEST 2024
1000 Vgl. frl:6473669
1000 Oai Id
  1. oai:frl.publisso.de:frl:6473669 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source